Table 2.
Cross tabulation of treatment HR (95% CrI) for OS, OSX, and PFS
| Drug | T-DM1 | Neratinib | Cap | LapCap | TrasCap | PerTrasCap |
|---|---|---|---|---|---|---|
| T-DM1 |
OS: 0.60 (0.32, 1.14) |
OS: 0.68 (0.39, 1.10) |
OS: 0.76 (0.51, 1.07) |
OS: 0.78 (0.44, 1.19) |
OS: 1.03 (0.51, 1.82) |
|
|
OSX: 0.56 (0.28, 1.10) |
OSX: 0.59 (0.33, 1.00) |
OSX: 0.69 (0.46, 1.08) |
OSX: 0.70 (0.38, 1.16) |
OSX: 0.93 (0.42, 1.73) |
||
|
PFS: 0.55 (0.28, 1.24) |
PFS: 0.38 (0.19, 0.74) |
PFS: 0.65 (0.40, 1.10) |
PFS: 0.62 (0.34, 1.18) |
PFS: 0.74 (0.32, 1.76) |
||
| Neratinib |
OS: 1.65 (0.88, 3.11) |
OS: 1.13 (0.58, 2.09) |
OS: 1.25 (0.76, 2.13) |
OS: 1.30 (0.67, 2.35) |
OS: 1.70 (0.79, 3.54) |
|
|
OSX: 1.80 (0.91, 3.57) |
OSX: 1.05 (0.52, 2.01) |
OSX: 1.25 (0.72, 2.10) |
OSX: 1.26 (0.65, 2.24) |
OSX: 1.66 (0.76, 3.29) |
||
|
PFS: 1.82 (0.81, 3.58) |
PFS: 0.69 (0.33, 1.34) |
PFS: 1.18 (0.65, 2.01) |
PFS: 1.12 (0.55, 2.10) |
PFS: 1.33 (0.56, 2.92) |
||
| Cap |
OS: 1.47 (0.91, 2.54) |
OS: 0.88 (0.48, 1.72) |
OS: 1.11 (0.79, 1.63) |
OS: 1.15 (0.76, 1.61) |
OS: 1.51 (0.82, 2.59) |
|
|
OSX: 1.70 (1.00, 3.04) |
OSX: 0.95 (0.50, 1.93) |
OSX: 1.18 (0.85, 1.69) |
OSX: 1.19 (0.79, 1.68) |
OSX: 1.57 (0.84, 2.66) |
||
|
PFS: 2.62 (1.35, 5.19) |
PFS: 1.45 (0.75, 2.99) |
PFS: 1.71 (1.11, 2.72) |
PFS: 1.62 (1.02, 2.56) |
PFS: 1.94 (0.96, 3.81) |
||
| LapCap |
OS: 1.32 (0.93, 1.98) |
OS: 0.80 (0.47, 1.32) |
OS: 0.90 (0.61, 1.26) |
OS: 1.04 (0.73, 1.37) |
OS: 1.36 (0.77, 2.19) |
|
|
OSX: 1.45 (0.93, 2.19) |
OSX: 0.80 (0.48, 1.39) |
OSX: 0.85 (0.59, 1.18) |
OSX: 1.01 (0.68, 1.35) |
OSX: 1.34 (0.74, 2.18) |
||
|
PFS: 1.54 (0.91, 2.52) |
PFS: 0.85 (0.50, 1.54) |
PFS: 0.59 (0.37, 0.90) |
PFS: 0.95 (0.66, 1.30) |
PFS: 1.13 (0.57, 2.17) |
||
| TrasCap |
OS: 1.28 (0.84, 2.27) |
OS: 0.77 (0.42, 1.49) |
OS: 0.87 (0.62, 1.32) |
OS: 0.96 (0.73, 1.37) |
OS: 1.31 (0.85, 2.01) |
|
|
OSX: 1.42 (0.86, 2.60) |
OSX: 0.80 (0.45, 1.55) |
OSX: 0.84 (0.59, 1.27) |
OSX: 0.99 (0.74, 1.47) |
OSX: 1.32 (0.85, 2.02) |
||
|
PFS: 1.62 (0.85, 2.97) |
PFS: 0.89 (0.48, 1.83) |
PFS: 0.62 (0.39, 0.98) |
PFS: 1.05 (0.77, 1.53) |
PFS: 1.20 (0.71, 1.94) |
||
| PerTrasCap |
OS: 0.97 (0.55, 1.96) |
OS: 0.59 (0.28, 1.26) |
OS: 0.66 (0.39, 1.22) |
OS: 0.74 (0.46, 1.30) |
OS: 0.76 (0.50, 1.17) |
|
|
OSX: 1.07 (0.58, 2.37) |
OSX: 0.60 (0.30, 1.32) |
OSX: 0.64 (0.38, 1.19) |
OSX: 0.75 (0.46, 1.36) |
OSX: 0.76 (0.50, 1.18) |
||
|
PFS: 1.34 (0.57, 3.09) |
PFS: 0.75 (0.34, 1.78) |
PFS: 0.52 (0.26, 1.04) |
PFS: 0.88 (0.46, 1.77) |
PFS: 0.83 (0.52, 1.41) |
HR < 1 indicates a better outcome with the drug in column 1 than with the comparator drug (columns 2–7)
Cap capecitabine, CrI credible interval, HR hazard ratio, Lap lapatinib, OS overall survival, OSX OS adjusted for crossover, Per pertuzumab, PFS progression-free survival, T-DM1 trastuzumab emtansine, Tras trastuzumab